author-photo

Raymond S. Douglas

Cedars-Sinai Medical Center

26

Papers

267

Citations

Citation Trend

Filter By

Papers (26) Sort By

Journal Conference Others

Teprotumumab for the treatment of thyroid eye disease: Clinical experience from expanded access program (EAP)

2021 Investigative Ophthalmology & Visual Science
Show All
- Source
- Cite
- Save
Citations (0)
Teprotumumab for thyroid eye disease: early response is not required for benefit

2021 Eye
Show All
- Source
- Cite
- Save
Citations (0)
Teprotumumab for the treatment of chronic thyroid eye disease.

2021 Eye
Show All
- Source
- Cite
- Save
Citations (1)
Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab.

2021 Plastic and reconstructive surgery. Global open
Show All
- Source
- Cite
- Save
Citations (0)
The Prominent Eye-What to Watch Out For.

2021 Facial Plastic Surgery Clinics of North America
Show All
- Source
- Cite
- Save
Citations (0)
The Spectrum of Aesthetic Canthal Suspension.

2021 Facial Plastic Surgery Clinics of North America
Show All
- Source
- Cite
- Save
Citations (0)
Teprotumumab use in a real-world setting: Expanded access program findings

2021 Investigative Ophthalmology & Visual Science
Show All
- Source
- Cite
- Save
Citations (0)
Teprotumumab for Asymmetric Thyroid Eye Disease.

2021 Ophthalmology
Show All
- Source
- Cite
- Save
Citations (0)
Improvement of asymmetric thyroid eye disease with teprotumumab.

2021 British Journal of Ophthalmology
Show All
- Source
- Cite
- Save
Citations (3)
Meta-Analysis of Proptosis Response in Thyroid Eye Disease: Efficacy of EUGOGO Recommended Treatment Regimen With IV Methylprednisolone

2021 Journal of the Endocrine Society
Show All
- Source
- Cite
- Save
Citations (0)